All Listed Conditions May Coexist with Resistant Hypertension
All five pathological conditions—heart failure, chronic kidney disease, pulmonary hypertension, obstructive sleep apnea, and peripheral artery disease—can coexist with resistant hypertension, though they vary in their frequency and mechanistic relationship to treatment resistance.
Most Common and Mechanistically Important Conditions
Obstructive Sleep Apnea (OSA)
OSA is one of the most prevalent conditions associated with resistant hypertension. In patients with true resistant hypertension, OSA affects 72.1% of patients (27% mild, 18.6% moderate, 26.5% severe) 1. The AHA guidelines explicitly recommend screening for OSA in all resistant hypertension patients, looking for snoring, witnessed apnea, and excessive daytime sleepiness 2. OSA contributes mechanistically through sympathetic nervous system overactivity 3.
Chronic Kidney Disease (CKD)
CKD is a well-established comorbidity that both contributes to and results from resistant hypertension. Only 37% of NHANES participants with CKD achieved blood pressure control to 130/80 mmHg 2. The guidelines specifically identify CKD (particularly creatinine clearance <30 mL/min) as a key screening target 2. CKD promotes treatment resistance through volume retention, RAAS activation, and altered drug metabolism 4, 3.
Diabetes Mellitus
While not listed in your options, diabetes deserves mention as it commonly coexists with resistant hypertension. In ALLHAT, diabetes predicted lack of blood pressure control, requiring an average of 2.8 to 4.2 antihypertensive medications to achieve goal 2.
Less Commonly Discussed but Clinically Relevant Conditions
Heart Failure
Heart failure coexists with resistant hypertension through bidirectional mechanisms. Resistant hypertension increases cardiovascular mortality risk by 10.3% absolute risk at 5-10 years 5, with heart failure being a major outcome. The guidelines note that bilateral renal artery stenoses should be suspected in patients with "flash" or episodic pulmonary edema, especially with preserved systolic function 2. Heart failure with reduced ejection fraction influences treatment selection (e.g., hydralazine with isosorbide) 6.
Peripheral Artery Disease (PAD)
PAD represents atherosclerotic disease burden that commonly accompanies resistant hypertension. The guidelines recommend screening for renal artery stenosis in patients with known atherosclerotic disease 2, and a history of peripheral or coronary atherosclerosis should raise suspicion for renovascular hypertension 2. PAD reflects the same vascular pathology (endothelial dysfunction, arterial stiffness) that contributes to treatment resistance 3.
Pulmonary Hypertension
While not explicitly detailed in the resistant hypertension guidelines, pulmonary hypertension can coexist through several mechanisms:
- Left heart disease from long-standing systemic hypertension causing secondary pulmonary hypertension
- Shared risk factors like OSA (which causes both systemic and pulmonary hypertension)
- The "flash pulmonary edema" mentioned in bilateral renal artery stenosis 2 implies pulmonary vascular involvement
Clinical Algorithm for Evaluation
When evaluating resistant hypertension, systematically screen for:
OSA (present in >70% of cases): Ask about snoring, witnessed apnea, daytime sleepiness, neck circumference >40 cm 3
CKD (affects control in majority): Check creatinine clearance, particularly if <30 mL/min 2
Atherosclerotic disease (PAD, coronary disease): Assess for differential pulses, bruits, history of vascular events 2
Heart failure signs: Evaluate for volume overload, preserved vs. reduced ejection fraction, episodic pulmonary edema 2, 6
Metabolic syndrome (present in 65.7% of resistant hypertension): Assess obesity, diabetes, dyslipidemia 1
Key Clinical Pitfall
The most common error is failing to recognize that resistant hypertension is almost always multifactorial 2. In the RESIST-POL study, the vast majority of patients with true resistant hypertension had at least one of three comorbidities: OSA, metabolic syndrome, or primary aldosteronism 1. Don't stop after finding one condition—continue systematic evaluation for overlapping pathologies that require targeted treatment beyond simply adding more antihypertensive medications.